Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 708 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IT Injection Clear all
Active, not recruiting Phase 1Phase 2 Interventional

PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717

NCT06153966
View directory record Official record
Conditions
Prion Disease
Interventions
ION717, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 5:38 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Systems Biological Analysis of Immune Responses to RSV Vaccine

NCT07185399
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Moderna RSV vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
60 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Minimal Opioid Use After Total Hip Replacement (THR)

NCT03090152
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)

NCT01494701
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 14 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies

NCT04258631
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm
Interventions
Hydromorphone, Laparotomy, Liposomal Bupivacaine, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 23, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional Results available

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT01186328
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
Interventions
EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.

NCT01066637
View directory record Official record
Conditions
Patients With Post Orthotopic Heart Transplantation Status
Interventions
[18F](+/-)NOS
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 23, 2026, 5:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574
View directory record Official record
Conditions
Type 1 Diabetes, New Onset
Interventions
Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
9 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 5:38 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT07290062
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
INS1202
Genetic
Lead sponsor
Insmed Gene Therapy LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 3 Interventional

Automated Insulin Delivery for Inpatients With Dysglycemia

NCT06418880
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
AID system with Remote Real-Time CGM, Standard of Care Insulin Therapy + CGM
Device · Combination Product
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional Results available

Examining Bioactivity of PVSRIPO in Invasive Breast Cancer

NCT03564782
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
PVSRIPO
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

NCT00911859
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib), Melphalan, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 23, 2026, 5:38 PM EDT
Active, not recruiting Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) for Health

NCT04430257
View directory record Official record
Conditions
Substance Dependence, HIV (Human Immunodeficiency Virus)
Interventions
HIV and PrEP education, Motivational interviewing, Problem-solving and planning, Patient navigation, PrEP information, Referrals
Other · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Cambridge, Massachusetts • Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Beetroot Juice for Boosting Immunity During a Time of Stress.

NCT06434181
View directory record Official record
Conditions
Healthy
Interventions
Beetroot Juice, Placebo Control
Dietary Supplement
Lead sponsor
Baylor University
Other
Eligibility
18 Years to 40 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Dallas, Texas • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

NCT02538341
View directory record Official record
Conditions
Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
Interventions
Herpes Zoster (HZ) Vaccine, Placebo
Biological · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 23, 2026, 5:38 PM EDT
Terminated No phase listed Observational

PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning

NCT03286972
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
PET/MRI
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy

NCT01240200
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Glargine, glargine via insulin pen
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 23, 2026, 5:38 PM EDT
Withdrawn Phase 4 Interventional

Single Shot Exparel vs Catheters in Lower Extremity Trauma

NCT07221019
View directory record Official record
Conditions
Fracture Dislocation of Ankle Joint, Fracture Leg, Fracture Femur, Fracture Lower Leg, Fracture
Interventions
Bupivacaine, Exparel + Bupivacaine
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Effect of Nitrous Oxide in Treating Neuropathic Pain: A Study in Chronic Low Back Pain Patients

NCT01172600
View directory record Official record
Conditions
Low Back Pain, Radiating Pain
Interventions
Entonox, Oxygen
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 23, 2026, 5:38 PM EDT
Recruiting Phase 2 Interventional

DaxibotulinumtoxinA for Blepharospasm

NCT07489430
View directory record Official record
Conditions
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions
Botulinum Neurotoxin Type A
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)

NCT04428281
View directory record Official record
Conditions
Angelman Syndrome
Interventions
RO7248824
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 12 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RHA Redensity - Perioral Rhytids

NCT03092219
View directory record Official record
Conditions
Perioral Rhytids, Aging, Wrinkle
Interventions
TEOSYAL RHA Redensity
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
6
States / cities
Beverly Hills, California • Santa Monica, California • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 23, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Trial Testing Buzzy Bee vs Vapocoolant During IV Placement

NCT06182631
View directory record Official record
Conditions
Intravenous Administration
Interventions
Buzzy Bee, Vapocoolent, Placebo
Device · Drug · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
6 Years to 18 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 23, 2026, 5:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

NCT04626635
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 5:38 PM EDT